Drug Search Results
More Filters [+]

Cilofexor

Alternative Names: cilofexor, gs-9674, gs9674, gs 9674
Latest Update: 2024-05-07
Latest Update Note: PubMed Publication

Product Description

Nonsteroidal FXR Agonist

Mechanisms of Action: FXR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cilofexor

Countries in Clinic: Australia, Canada, France, Japan, Puerto Rico, Spain, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Cholangitis, Sclerosing

Phase 2: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

WAYFIND

P2

Active, not recruiting

Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic

2024-11-01

24%

WAYFIND

P2

Active, not recruiting

Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic

2024-11-01

24%

2021-001445-12

P2

Active, not recruiting

Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic

2024-08-27

jRCT2071210112

P2

Recruiting

Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic

2024-07-31

JapicCTI-194804

P3

Active

Cholangitis, Sclerosing

2023-02-28

Recent News Events